Swedish medical technology company Getinge has received the US Food and Drug Administration (FDA) for Servo-air Lite, a non-invasive wall gas mechanical ventilator.

Getinge said that its Servo-air Lite is a turbine-driven critical-care ventilator, developed based on its advanced Servo family of ventilators.

The non-invasive ventilator offers ICU-quality ventilation, with a special focus on providing extra breathing support to spontaneously breathing patients.

The Swedish company said that with a powerful turbine and long-lasting battery, the ventilator can be used for both non-invasive and invasive ventilation and is suitable for intrahospital transports.

Getinge plans to commercialise the mechanical ventilator in the US from September this year.

Getinge acute care therapies president Elin Frostehav said: “We are happy to broaden our ventilator product offering for the US market.

“This significantly increases our addressable ventilation market in the US, by now being able to target the non-invasive hospital segment with our ventilation offering.”

According to Getinge, its Servo-air Lite mechanical ventilator can be operated independently of wall gas or power outlets.

The equipment provides easy access to High Flow therapy, Servo Compass, CO2 monitoring and other important customised ventilation tools offered through the company’s advanced models.

The Servo-air Lite ventilator also features embedded workflows, and monitoring options along with necessary tools to support escalation of therapy if needed.

Its powerful and quiet turbine-driven design is said to prevent interruptions and ensures sustained flow and unusually high power.

Furthermore, the ventilator’s hot-swappable batteries will provide backup power, and can also be connected through a cylinder if more oxygen is required, without switching devices.

Earlier this year, Getinge received the US FDA premarket approval for its iCast-covered stent system to treat patients with iliac arterial occlusive disease.